1. Introduction {#sec1}
===============

Coronary heart disease (CHD) is the main cause of death globally; it is estimated that 17.9 million people died of cardiovascular diseases (CVDs) in 2016, representing 31% of all global deaths. The basic pathophysiology process is atherosclerosis, which tends to create plaque and block vascular cavity, resulting in myocardial ischemia, hypoxia or necrosis. Presently, the therapies for CHD mainly include coronary artery intervention (PCI) or coronary artery bypass grafting (CABG) \[[@B1]\]. However, postsurgical restenosis and low operative tolerance of aging and patients with extensive lesions limit its efficacy in CHD. Therefore, it is important to search for other alternative methods. Ischemic zones can actually recover blood perfusion by recruiting new vessels or expanding and remodeling produce arterioles; this process is also called revascularization and includes angiogenesis and arteriogenesis \[[@B2]\]. The mechanism of these processes has been widely studied. Angiogenesis is induced by hypoxia and involves three cells: tip cells, stalk cells, and phalanx cells \[[@B3]--[@B5]\], while the main stimulus of arteriogenesis is fluid shear stress (FSS), which is sensed by endothelial cells and consequently attracts leukocytes and promotes the phenotype transformation of vascular smooth muscle cells (VSMCs) \[[@B6]--[@B9]\]. Signal pathways of these two ways both include vascular endothelial growth factor (VEGF) pathway and nitric oxide- (NO-) dependent pathway \[[@B10]--[@B14]\] and both of them can be regulated by a highly conserved eukaryotic kinase, 5′adenosine monophosphate-activated protein kinase (AMPK) \[[@B15]--[@B17]\]; SNF1 and SnRK1 are its orthologues in yeast and several plants \[[@B18]\].

AMPK, a heterotrimeric complex combined by *α*, *β*, *γ* subunits, is activated by upstream kinases and regulated by the ratio of ADP/ATP or AMP/ATP or posttranslational modifications including phosphorylation and ubiquitylation, which exerts vital roles in maintaining energy homeostasis, protecting endothelial cellular function, regulating cellular autophagy, oxidative stress, and aging \[[@B19]\]. AMPK is ubiquitously expressed in a lot of tissues and cells, such as the endothelial cells (ECs), skeletal muscle, liver, and brain \[[@B20]\]. The roles of AMPK in revascularization have been widely researched, and it seems that the findings are varying in different conditions. In ischemia or hypoxia, AMPK activation facilitates angiogenesis but in tumor microenvironment inhibits it. Similarly, some findings show that AMPK promotes arteriogenesis by regulating inflammation but others suggest AMPK play a negative role in collateral circulation \[[@B15], [@B17]\].

2. AMPK {#sec2}
=======

2.1. Subunits of AMPK {#sec2.1}
---------------------

AMPK, a heterotrimeric protein complex, includes *α* subunit (encoded by protein kinase AMP-activated-*α* (PRKAA)) \[[@B21]\], *β* (PRKAB) \[[@B22]\], and *γ* (PRKAG) \[[@B23]\]. These isoforms play distinct roles in the AMPK stability and activity, but all three are essential for full activity. *α* (two isoforms) are catalytic subunits; *β* subunit (two isoforms) and *γ* subunit (three isoforms) contain the regulatory site, which could be combined by 12 various ways \[[@B24]\].

Both *α* subunits are similar in that their *N* termini have traditional serine/threonine kinase domains (*α*-KD) as well as the conserved threonine residue (*α*1 Thr183 and *α*2 Thr172), which are key phosphorylated sites \[[@B25]\]. The following are the inhibitory domains (*α*-AID), which negatively regulate AMPK. The C termini of AMPK is C-terminal domain (*α*-CTD) with nuclear export sequence (NES), whose crystal structure has not been resolved. Between *α*-AID and *α*-CTD is "*α* linker," which is locked around the *γ* subunit ([Figure 1](#fig1){ref-type="fig"}). These two isoforms have various subcellular locational pattern; *α*1 isoform majorly appears to distribute in the cytoplasm or to associate with the plasma membrane of carotid body type 1 cells. However, *α*2 prefers locating in the nuclei of some cell types, such as skeletal muscle \[[@B26]\]. They have specificity of tissue distribution; for instance, AMPK*α*1 isoform is in the adipose tissue \[[@B27]\] while skeletal muscle expresses much higher AMPK*α*2 \[[@B28]\]. Interestingly, ECs have both of these isoforms, although AMPK*α*1 predominates at a much higher level than AMPK*α*2 \[[@B29]\].

Most of the parts of *β* subunits are highly conserved except the first 65 residues of NH2-terminus. AMPK*β*1 is nearly expressed in all cell types while *β*2 is mainly distributed in muscle. From N-terminus to C-terminus, *β* subunits have myristoylated N-terminal regions, carbohydrate-binding modules (*β*-CBM), *β*-linker regions, and the C-terminal domains (*β*-CTD) ([Figure 1](#fig1){ref-type="fig"}) \[[@B22], [@B30]\]. The crystal structures of *β*-CBM and *β*-CTD are completely resolved but the structures of N-terminal regions and *β*-linker are still unclear. Significantly, there is compelling evidence that N-terminal myristoylation of *β* subunits plays an indispensable role in AMPK lysosomal localization and activation in an AMP/ADP/ATP-independent manner in the process of glucose depletion \[[@B31], [@B32]\]. And N-myristoylation of AMPK *β* subunits also controls T cell inflammatory function \[[@B33], [@B34]\]. Hardie et al. have demonstrated that glycogen inhibits AMPK activation by binding the *β*-CBM of AMPK, which suggest that AMPK equilibrates cellular energy by sensing not only the change of AMP/ATP or ADP/ATP but also glycogen \[[@B35]\]. *β*-CTD interacts with *γ* N-terminal regions, which let AMPK become an intact complex to exert its normal function \[[@B36]\].

Although *γ* subunits have different lengths (*γ*1 331 \< *γ*3 489 \< *γ*2 569 residues), each one shares the same COOH-terminal having about 300 residues, a variable N-terminal domain that interacts with *β*-CTD and four tandem repeats of a motif termed CBS repeat ([Figure 1](#fig1){ref-type="fig"}) \[[@B18]\]. Excepting CBS2 which is an unoccupied site, CBS1, CBS3, and CBS4 could be bound by AMP or ATP by different affinities, CBS1 site binds ATP with higher affinity, but CBS3 site has higher affinity for AMP, and CBS4 is believed to be a nonchangeable site; that is, it binds AMP irreversibly \[[@B37], [@B38]\]. Furthermore, different isoforms of *γ* subunits also have distinct affinity with AMP, such as *γ*3 which is the least sensitive \[[@B39]\]. Like *α* and *β* subunits, *γ* subunits also have tissue distribution specificity; *γ*1 subunit is widely expressed in all tissues, whereas *γ*2 and *γ*3 isoforms are mainly abundant in skeletal muscle \[[@B40]\].

In conclusion, both *α*1 and *α*2 subunits have a crucial site in Thr183 and Thr172, whose phosphorylation is necessary for AMPK maximal activation. The *β* subunits could act as a scaffold, which makes AMPK complex locate on lysosomes, except for having phosphorylation, myristoylation, and carbohydrate-binding sites \[[@B18]\]. The *γ* subunits bind the nucleotides by three sites, which are structural basis for this energy sensor. Most importantly, the catalytic features of *α* subunit and regulatory activity of *β* and *γ* subunits are all integrant for AMPK correct and normal activation.

2.2. Activation of AMPK {#sec2.2}
-----------------------

AMPK is activated mainly by three complementary mechanisms: (1) allosteric activation \[[@B41]--[@B43]\]; (2) phosphorylation of *α*1 Thr183 or *α*2 Thr172 \[[@B25]\]; and (3) inhibiting dephosphorylation of Thr183 or Thr172 \[[@B44]\].

Mammalian AMPK is sensitive to the changes of AMP/ATP or ADP/ATP. Therefore, any cellular metabolic process that reduced ATP levels or increased AMP/ADP can activate AMPK, such as hypoxia, glucose decrease, mitochondrial oxidative stress, or metabolic inhibition of ATP synthesis \[[@B20], [@B45]\]. However, Lin and Hardie et al. found that AMPK can be activated through an additional AMP-/ADP-independent mechanism in response to glucose reduction both in vivo and in vitro \[[@B31]\]. They demonstrated that different compartmentalized pools of AMPK are activated through distinct ways, which depends on the extent of elevation of cellular AMP \[[@B46]\]. Low increases in AMP activate AMPK only via the AMP-independent, AXIN-based manner in lysosomes, which is regulated by fructose-1,6-bisphosphate (FBP) levels. When FBP decreases, adolase is released and then interacts with vacuolar-type H + -ATPase (V-ATPase), Ragulator, and AMPK-AXIN-LKB1 and finally becomes a complex and activates AMPK. Mild concentrations of AMP also enlarge this to activate cytosolic AMPK by an AXIN-dependent pathway. By comparison, severe glucose starvation activates all pools of AMPK in the AMP-/ADP-dependent manner rather than AXIN. Researches demonstrated a space-time basis for hierarchical activation of AMPK in various compartments in the process of differing the extents of energy stress \[[@B47]\]. But the question of how the FBP-free status of adolase binds vacuolar-type H + -ATPase (V-ATPase) has not been illuminated. Excitedly, Lin and Hardie et al. recently suggested that transient receptor potential cation channels (TRPVs), in low glucose, relay the adolase to the reconfiguration of v-ATPase, activating AMPK \[[@B48]\]. Although *α* subunit is catalytic, more and more evidence finds that regulatory *β* and *γ* subunits also are essential for AMPK optimum function. For example, N-myristoylation of *β* subunits is necessary for lysosome location of AMPK complex \[[@B31]\].

Besides allosteric activation, upstream two major AMPK kinases, which are liver kinase B1 (LKB1) \[[@B48]\], also known as serine/threonine kinase 11 (STK11) or renal carcinoma antigen NY-REN-19, and the Ca^2+^/calmodulin-dependent protein kinase kinase *β* (CaMKK*β*) \[[@B49]\] can regulate AMPK*α* activity through a phosphorylated manner. Researches reveal phosphorylation of the *α* subunit can depend on, or independently of, its LKB1 activity. CaMKK*β* is activated by intracellular concentration of Ca^2+^ \[[@B50], [@B51]\]. Thus, stimuli that magnify this, such as bradykinin \[[@B52]\] and thrombin \[[@B53]\], also phosphorylate AMPK*α* subunit in an AMP-/ADP-independent way owing to increased CaMKK*β* activity. It is worth mentioning that ubiquitination modification also regulates AMPK*α* activation. Zhenkun Lou et al. have found that AMPK*α*1 or AMPK*α*2 ubiquitination blocks its phosphorylation by LKB1, which could be rescued by the deubiquitinase ubiquitin specific peptidase 10 (USP10) \[[@B54]\]. Other researchers also have shown that AMPK*α*2 is ubiquitinated by ubiquitin-conjugating enzyme E2O (UBE2O) in a mouse model of breast cancer, which activates the mammalian target of rapamycin-hypoxia inducible factor 1-*α* (mTOR-HIF1-*α*) pathway and triggers cancer growth \[[@B55]\]. Similarly, AMPK*α*1 is also ubiquitinated and degraded by MAGE-A3/6-TRIM28 E3 ubiquitin ligase complex \[[@B56]\].

Briefly, in the case of replete energy, that is, low AMP/ATP or ADP/ATP, phosphatases can keep AMPK*α*1 Thr183 or *α*2 Thr172 in an unphosphorylated state by accessing to it. However, when energy decreases, CBS of the AMPK *γ* subunit is occupied by AMP or ADP, which prohibits the phosphatases from dephosphorylating Thr183 or Thr172, therefore increasing AMPK activity. It is worth mentioning that unlike AMP, ADP has no conspicuous allosteric effect on AMPK \[[@B44], [@B57]\].

2.3. Downstream Targets of AMPK {#sec2.3}
-------------------------------

Downstream targets of AMPK mainly include molecules involving glucose, lipid, protein metabolism or inflammation, oxidative stress, and aging process.

During lipid metabolism, once being activated, AMPK as a serine/threonine kinase phosphorylates some crucial molecules that regulate lipid metabolism, such as acetyl-CoA carboxylase (ACC) \[[@B58]\], 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase) \[[@B42]\], and sterol regulatory element-binding protein 1c (SREBP1c) \[[@B59]\]. Except for the above-mentioned molecules, evidence has shown that AMPK reduces hepatic steatosis in high-fat, high-sucrose (HFHS) diet-fed mice by interacting with and mediates phosphorylation of insulin-induced gene (Insig), a novel effector of AMPK, which plays a critical role in regulating intracellular cholesterol equilibrium \[[@B60]\]. Furthermore, activated AMPK also stimulates skeletal muscle to uptake glucose by phosphorylating Rab-GTPase-activating protein TBC1 domain family member 4 (TBC1D4), which ultimately induces fusion of glucose transporter type 4 (GLUT-4) vesicles with the plasma membrane \[[@B61]\], and phosphorylates 6-phosphofructo-2-kinase (PFK-2) \[[@B62]\], glycogen, and glycogen synthase to promote glycolysis and inhibit glycogen synthesis. In addition, AMPK suppresses the energy-intensive protein biosynthesis process by phosphorylating tuberous sclerosis complex 2 (TSC2) which regulates activity of mammalian target of rapamycin complex 1(mTORC1) promoting protein synthesis \[[@B20], [@B63]\]. AMPK regulates autophagy by directly and indirectly activating Unc-51 like autophagy activating kinase (ULK1) \[[@B64], [@B65]\] and mitochondrial biogenesis by regulating peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1*α*) which in turn promotes gene transcription in the mitochondria \[[@B66], [@B67]\]. AMPK participates in the cellular redox regulation and anti-inflammation response. Hong Li et al. have depicted that the Cys130 and Cys174 of AMPK*α* is oxidized during energy stress, which could be inhibited by Thioredoxin1 (Trx1) and protects AMPK activation in ischemia \[[@B68], [@B69]\]. In some inflammatory disease, AMPK also impacts a positive role, such as allergic diseases \[[@B68]\], monosodium urate (MSU) crystal-induced inflammation \[[@B70]\], and synovitis \[[@B33]\]. The process of aging, involving inflammation, oxidative stress, metabolic disorder, and decrease of autophagic clearance, is of course using AMPK as a supervisor that orchestras all the pathways in order to resist bad effects of senescence \[[@B71]\]. For instance, skeletal muscle AMPK knockdown-aged mice show hypoglycemia and hyperketosis during fasting \[[@B72]\].

3. The Mechanism of Revascularization {#sec3}
=====================================

After the initiation of ischemia, cardiac or skeletal muscle undergoes a series of molecules and hemodynamical changes triggered by hypoxia-related pathways \[[@B10]\], invasion and infiltration inflammatory cells \[[@B73], [@B74]\], and cellular metabolism remodeling \[[@B75], [@B76]\], to promote capillary neogenesis (angiogenesis), or arterioles remodeling (arteriogenesis or collateral circulation), and then eventually to restore blood perfusion of ischemic zones.

Angiogenesis is induced by hypoxia via HIF1-*α*, which depicts the formation of new capillaries by sprouting or splitting from preexistent vessels, which is different from vasculogenesis \[[@B3], [@B5]\]. The latter is a process of endothelial cells from mesoderm cell precursors which form primitive tubules during the embryonic phase \[[@B10], [@B77], [@B78]\]. The process of angiogenesis is completed mainly by three EC subtypes. (1) Firstly, "tip cells" featured migratory capability sense proangiogenic stimuli, such as VEGF, fibroblast growth factor (FGF), and led the newly forming vessel to sprout towards the source of the proangiogenic stimuli. (2) During the migration of the tip cells, proliferative "stalk cells" lengthen neovessels. When neighbouring vessels\' sprouts meet and their tip cells fuse, an interconnected, closed, and functional lumen allowing blood flow is formed. (3) Next, the quiescent "phalanx cells" mature neovessels featured by a typical cobblestone shape. (4) Finally, in order to form a tighter vessel for proper stability and barrier function, pericytes secrete platelet-derived growth factor-B (PDGF-B) and subsequently recruit VSMC expressing PDGF receptor *β* \[[@B79], [@B80]\]. Recently, the roles of metabolism remodeling of endothelial cells in angiogenesis are attached by many researchers. For example, Katrien and Yiming Xu et al. have found that endothelial 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, isoform 3, (PFKFB3) plays a critical role in vessel sprouting and angiogenesis \[[@B81], [@B82]\].

Arteriogenesis or collateral growth, being different from angiogenesis, is a process that the existing interconnected vascular branches between adjacent blood vessels expand and remodel triggered by FSS, which is induced by increased flow across the collateral bed; when the main coronary artery is occluded, the downstream pressure decreases, resulting in an increased pressure drop and flow velocity across collaterals \[[@B83]--[@B85]\]. The basic pathophysiological courses of arteriogenesis contain the following. (1) Endothelial cells sense elevated FSS, which is the initiated step of arteriogenesis formation, by some molecules including Trpv4 \[[@B86]\], actin-binding rho activating protein (Abra) \[[@B87]\], and then change morphology and express multiple genes mainly participating in attracting circulatory blood cells and promoting cells adhesion, such as selectins, chemokine (C-C motif) ligand 2 (CCL2), intercellular adhesion molecules (ICAM), vascular cell adhesion molecules (VCAM-1), and VEGF. (2) The second one is inflammatory cell invasion and infiltration; for example, Florian P. Limbourg et al. suggest that endothelium matures macrophage and controls macrophage differentiation via Notch signaling, which in turn promotes arteriole growth \[[@B88]\], and neutrophils signal is enhanced at early ischemic phase \[[@B89]\]. (3) The third is VSMC proliferation, migration, and phenotypic transformation \[[@B6], [@B7]\]. Although a considerable number of researches using multifarious animal models have uncovered the signaling pathways of arteriogenesis involving the VEGF, PDGF, NO, and rho-pathway \[[@B87], [@B90]\], clinical trials are somehow disappointing \[[@B91]\].

4. AMPK in Endothelial Cells {#sec4}
============================

ECs, mostly remaining quiescent throughout adult life, retain the capacity to rapidly form new blood vessels in response to injury or in pathological conditions such as hypoxia, ischemic, and hemodynamic changes. They then can respond with suitable regulatory and control processes to maintain cellular or systematic homeostasis. Such responses contain secretion of angiogenic factors promoting proliferation, migration of ECs, differentiation of endothelial progenitor cells (EPCs), or remodeling of endothelial metabolism.

It is widely believed that ECs prefer generating ATP through oxidative phosphorylation to produce more energy (the ratio of ATP yielded by oxidative phosphorylation and glycolysis is 30 : 2 or 32 : 2). In fact, ECs have a lower mitochondrial content and depend primarily on glycolysis \[[@B92]\]. Although the level of ATP per glucose generated is relatively low, high glycolytic flux can generate more ATP at a faster rate than oxidative phosphorylation when glucose is sufficient and is positioned to shunt glucose into glycolysis side branches to synthesize macromolecule such as the hexosamine and pentose phosphate. More advantages of aerobic glycolysis in ECs may include (1) generating less reactive oxygen species (ROS) by decreasing aerobic oxidation, (2) preserving maximal amounts of oxygen to supply perivascular cells, (3) making ECs adapt hypoxic environment they will grow into, and (4) producing lactate which is a proangiogenic signaling molecule \[[@B80], [@B93]--[@B95]\]. Except for glucose, another fuel source for ECs is fatty acids. Given the fact that it modestly contributes total ATPs in ECs, the exact role of fatty acids in ECs is elusive at present and needs more attention in the future. For example, Ulrike et al. show that fatty acid synthase knockdown (FASN^KD^) in ECs impedes vessel sprouting by reducing proliferation \[[@B76]\]. AMPK, as an energy and embolism gauge, can also phosphorylate key rate-limiting enzymes of the above-mentioned anabolism pathways in ECs, and as such the relationship between the AMPK and the ECs metabolism in angiogenesis still needs to be lucubrated.

For amino acid metabolism, arginine is most broadly studied for its conversion to citrulline and NO. The latter is the essential signaling molecule for endothelial function, which is synthesized by endothelial NO synthase (eNOS). eNOS expression and activity are carefully regulated by multiple interconnected mechanisms at the transcriptional (binding of transcription factors, DNA methylation), posttranscriptional (primary transcript modifications, mRNA stability, and nucleocytoplasmatic transport), and posttranslational levels (phosphorylation, fatty acid acylation, and protein-protein interactions) \[[@B96]\]. Modification of phosphorylation is vital for eNOS activity. In this moment, AMPK is the only kinase identified that can probably phosphorylate eNOS on more than one site, that is, Ser1177 and Ser633 in the reductase domain and inhibitory Thr495 site in the CaM-binding domain of the enzyme. A body of researches have reported AMPK dependent eNOS phosphorylation (on Ser1177) can proceed the following diverse endothelial cell stimulation, such as peroxisome proliferator-activated receptors (PPAR) agonists, AICAR, metformin, VEGF, and adiponectin. It is worth noting that the effects are usually weaker and much less arresting than other stimulation, like thrombin, hypoxia, and shear stress, which also lead to AMPK activation \[[@B97], [@B98]\].

5. AMPK in Angiogenesis {#sec5}
=======================

The roles of AMPK in angiogenesis have not been clarified and somehow are contradictory. A considerable amount of evidence has shown that AMPK exerts its positive impact on angiogenesis mainly in the metabolic syndrome, ischemia diseases, and hypoxia. That mainly includes four parts. (1) It guarantees energy supply of endothelial cells. (2) AMPK regulates EPCs differentiation, ECs proliferation, and migration \[[@B99], [@B100]\]. (3) AMPK, acting as an upstream kinase, phosphorylates eNOS to produce NO, facilitating vascular vasodilation and angiogenesis \[[@B101]\]. (4) Activation of AMPK under hypoxic conditions promotes autophagy, which somehow enhances VEGF expression \[[@B102]\]. Some earlier studies report that AMPK*α*1 impedes anoxia-induced apoptosis \[[@B103], [@B104]\] and protects against diabetes mellitus-induced vascular injury by improving EPCs function and promoting reendothelialization through upregulation of heme oxygenase-1 and stromal cell-derived factor 1 (SDF1) \[[@B105], [@B106]\], and dominant negative AMPK mutants inhibit both ECs migration and differentiation in vitro under hypoxia and in vivo angiogenesis \[[@B103]\]. In addition, evidence has demonstrated that LKB1/AMPK improve blood perfusion by inducing angiogenesis in hind limbs ischemic model of mice \[[@B102], [@B107]\] ([Figure 2](#fig2){ref-type="fig"}). At present, protective roles of AMPK in angiogenesis or on ECs or EPCs under some adverse condition, such as anoxia, stroke, senescence, and oxidative stress, have been validated \[[@B20], [@B108]\], and it also can be stimulated by cytokines or pharmacological agents such as VEGF \[[@B109]\], AICAR \[[@B109]\], metformin \[[@B100]\], berberine \[[@B110], [@B111]\], and adiponectin \[[@B112]\].

However, other researches have also revealed the passive effects of AMPK on angiogenesis. Evidence has demonstrated that AMPK exerts protective roles on retinopathy. Activated AMPK protects retinal vasculature from edema, hemorrhage, and final retinal detachment by decreasing oxidative stress and inflammation, improving circulation in narrow arterioles, inhibiting angiogenesis \[[@B113]--[@B116]\]. Studies have shown that metformin inhibits laser-induced choroidal neovascularization by activating AMPK \[[@B117]\]. Similarly, AMPK, being activated by berberine, can inhibit modified LDL-induced injury of Müller cell \[[@B118]\], which is the major glia of the retina; they are maintaining the blood-retinal barriers (BRBs). In addition, a variety of researches have shown that AMPK activation by many pharmacological activators, such as compound C, metformin, AICAR, curcumin, and simvastatin, inhibits tumor invasion and metastasis via the blockage of angiogenesis \[[@B119]--[@B122]\]. Furthermore, antifungal drug itraconazole targets mitochondrial protein voltage-dependent anion channel 1 (VDAC1) to suppress angiogenesis by modulating the AMPK/mTOR signaling axis in endothelial cells \[[@B123]\]. Interestingly, there are some studies which have shown that AMPK activation by some agents may play a positive role in tumor growth, even including metformin \[[@B124], [@B125]\].

Whether AMPK activation promotes angiogenesis or inhibits it depends on different cellular microenvironment. Generally, activation of AMPK in ischemic or hypoxic conditions facilitates angiogenesis but in tumor microenvironment inhibits it, which is attributed to different pathway activation. For example, under ischemic or hypoxic condition, AMPK activation has a positive effect on autophagy by inhibiting mTOR and phosphorylating autophagy modulators \[[@B126]\]. Autophagy somehow stabilizes HIF-1*α*, which regulates VEGF and other angiogenic molecules, and promotes angiogenesis \[[@B127]\]. The signal pathway of mTOR-HIF-1*α*-VEGF is activated in cancer cells; metformin or other AMPK activators can impede them, inhibiting angiogenesis \[[@B128]\].

6. AMPK in Arteriogenesis {#sec6}
=========================

So far, there is not much evidence on the role of AMPK in arteriogenesis and the ones that exist are inconsistent. One line of evidence shows that AMPK*α*1(--/--) can impair adult arteriogenesis in that it reduces accumulation of macrophages in ischemic hindlimb and inhibits the expression of growth factors in macrophages \[[@B15]\]. However, another has shown that mitochondrial oxidative stress impedes coronary collateral growth in lean rats in response to repetitive ischemia through activating AMPK and consequently inhibiting mTOR signaling, which is necessary for new protein synthesis and phenotypic switching of endothelial cells \[[@B17]\]. These two cases hint that the effects of AMPK in arteriogenesis under different physiological or pathological circumstances need to be developed further. Researches have shown that FSS, as a key factor which promotes opening and remodeling of collateral circulation, could influence activity of AMPK. For example, Wei Yi et al. have found that FSS can impede the survival and increase the apoptosis of bone marrow mesenchymal stem cells (BMSCs), which partly is attributed to the decrease of AMPK phosphorylation \[[@B129], [@B130]\]. What is more, exercise, also as an important element for arteriogenesis \[[@B131]\], has been found to play a positive role in AMPK activation. Young has verified that, in physiological condition, rat cardiac AMPK activity increases progressively with exercise intensity \[[@B132]\]. More importantly, Ferguson has also found that interval and continuous sprint cycling promotes phosphorylation of human skeletal muscle AMPK *α*Thr172 \[[@B133]\] ([Figure 2](#fig2){ref-type="fig"}).

7. Prospect {#sec7}
===========

AMPK, as a key modulator of cellular energy, metabolism, and oxidative-redox homeostasis, plays a complicated regulatory role in the ECs. When AMPK is activated by elevated ratio of AMP/ATP or ADP/ATP, ROS, cytokines, or agents, the kinase will promote catalysis pathways, such as glycolysis, inhibit analysis pathways, such as glycogen or protein synthesis, and regulate inflammatory process and oxidative stress, through phosphorylation of some crucial enzymes such as eNOS, FASN, ACC, PFK-2, mTORC1, and ULK1. Although AMPK also participates in regulating revascularization, the effect of AMPK is contradictory. Generally, activated AMPK promotes angiogenesis in ischemia whereas inhibiting angiogenesis under retinopathy or tumor microenvironment. The role of AMPK during arteriogenesis also is double-faced, which is attributed to different intracellular or extracellular circumstances. Global knockout of AMPK*α*1 and macrophage-specific knockout mice, which are subjected to hindlimb ischemia brought about by femoral artery ligation, impairs adult arteriogenesis so that it reduces perfusion to the lower limb. However, if cells suffer mitochondrial oxidative stress, activated AMPK does not promote collateral growth; on the contrary, it suppresses arteriole opening or remodeling. As mentioned previously, although up until this moment there is no enough evidence that has shown the definite role of AMPK in arteriogenesis; given that both FSS and exercise also regulate AMPK phosphorylation, it is still worthy of exploring AMPK function in collateral circulation. What is more, AMPK, as a heterotrimeric protein complex, so far, has had many studies focus on the function of AMPK phosphorylation, while the role of other posttranslational modifications in revascularization need to be illuminated, such as ubiquitination, acetylization, and glycosylation. Different isoforms of AMPK may influence this process.
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![The structure of AMPK subunits: AMPK have three subunits, including *α*, *β*, *γ*. *α* is catalytic while *β* and *γ* are regulatory. Both *α*1 and *α*2 subunits have a crucial site in Thr183 and Thr172, whose phosphorylation is necessary for AMPK maximal activation. The *β* subunits could act as a scaffold, which makes the AMPK complex located on lysosomes, an exception from having phosphorylation, myristoylation, and carbohydrate-binding sites. The *γ* subunits bind the nucleotides by three sites, which are the structural basis for this energy sensor.](CRP2020-4028635.001){#fig1}

![The roles of AMPK in revascularization. After vessels are occluded, remote tissues suffer ischemia and hypoxia, the blood perfusion of collateral arterioles increases, and the FSS is elevated. FSS and hypoxia activate AMPK by different or the same ways.](CRP2020-4028635.002){#fig2}
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